HCV NS5A Testing

The HCV NS5A Drug Resistance Assay is a genotypic (sequencing) resistance assay that analyzes the nonstructural (NS) 5A region of hepatitis C virus (HCV) genotypes 1a or 1b using next-generation sequencing (NGS) techniques. Amino acid substitutions in the NS5A region are identified, and a viral susceptibility call for the direct-acting agents (DAAs) that inhibit the NS5A proteins is reported as either “resistance possible” or “none/undetermined”. Monogram offers NS5A testing for both HCV genotype 1 and HCV genotype 3 viruses. 

Features of HCV NS5A Drug Resistance Assay

  • Assessment of HCV susceptibility for currently available NS5A DAAs, including daclatasvir​, elbasvir, velpatsvir, pibrentasvir, ledipasvir and ombitasvir for HCV genotype 1 viruses
  • Assessment of daclatasvir​​, pibrentasvir and velpatasvir susceptibility for HCV genotype 3 viruses
  • Identification of amino acid variants within the NS5A protein of HCV genotypes 1a or 1b, or genotype 3a
  • Detection of mixtures of wild-type and drug-resistant variants when present at levels as low as 10% of the total population

Download NS5A Sample Reports

HCV NS5A Testing
Test Name Labcorp Test Number Limitation Specimen Collection
Hepatitis C Virus (HCV) NS5A Drug Resistance Assay 550325 For patients with HCV genotype (subtype) 1a or 1b and a viral load ≥ 500 IU/mL 2 mL plasma, EDTA or PPT tube, shipped frozen

Hepatitis C Virus (HCV) Genotype 3 NS5A Drug Resistance Assay


For patients with HCV genotype 3a and a viral load ≥ 500 IU/mL

2 mL plasma, EDTA or PPT tube, shipped frozen